Global Medtech Industry Faces Structural Reset in 2026

Executive Summary

Medical technology companies in 2026 face a complex mix of structural forces. China's volume-based procurement has moved from an access initiative to a global pricing reference. Procedures are shifting from hospitals to outpatient centers across health systems. Trade policy and tariffs are forcing supply chain redesign. GLP-1 therapies are changing patient behavior and care pathways. And platform-based digital technology is becoming a central driver of competitive strategy.

Introduction

The medtech industry has historically competed on clinical performance and product innovation. In the current environment, pricing, regulatory policy, trade, and digital ecosystems are equally important. This analysis reviews five trends from the Clarivate report, translating them into the broader context of global markets.

China's VBP Expansion is Redefining Global Market Economics

China's volume-based procurement, or VBP, is expanding in scope and sophistication. Originally established to increase patient access to affordable devices, it now uses more advanced anchor price logic, enforces significant price compression, and allocates volumes in a way that supports domestic manufacturers. No longer a local measure, the policy is becoming a major pricing benchmark for multinational companies operating across emerging and developed markets.

The consequences are important for global investment and strategy. Device makers must decide whether to compete in China under lower prices, develop differentiated local products, or withdraw from certain segments. Many Chinese manufacturers are using VBP as a springboard to strengthen innovation capacity and look outward to export markets. This dynamic is shifting the geography of medtech competition.

Outpatient and ASC Settings are Central to Procedure Strategy

Healthcare delivery is moving away from traditional inpatient hospitals toward ambulatory surgical centers and outpatient environments. In the United States, the Centers for Medicare & Medicaid Services has expanded the list of procedures covered in ASCs and is reducing inpatient-only categories. Cardiac ablation, spine procedures, and advanced orthopedic interventions are among the procedures becoming more accessible in lower-cost settings.

A similar trend is visible in other countries seeking to increase healthcare efficiency. Device companies must adapt their product engineering, regulatory approval strategy, and commercial model for a broader set of sites of care, many of which make purchasing decisions differently than hospitals.

Trade and Supply Chain Pressures are Transforming Manufacturing Strategy

Tariffs, geopolitical uncertainty, and volatile input costs are challenging longstanding manufacturing assumptions. Companies are diversifying suppliers and pursuing multi-region production footprints, often involving countries that offer trade advantages or lower geopolitical exposure. In addition, raw material costs for electronics, plastics, and metals are pressuring margins.

This trend carries huge implications for global FDI. Emerging economies that can offer stable trade agreements, skilled labor, and modern infrastructure are competing for medical device manufacturing projects. New supply chain patterns may also influence where innovation clusters develop.

The GLP-1 Effect is Reshaping Device Demand and Care Pathways

Glucagon-like peptide-1 therapies, or GLP-1 receptor agonists, have become a major force in metabolic health. Their popularity is changing referral patterns for bariatric surgery and other weight-related procedures. Some surgical volumes are slowing, while other disease areas are seeing new monitoring and treatment requirements. Sleep apnea, cardiovascular disease, and diabetes are connected to the broader effects of weight reduction and metabolic therapy.

Medtech companies should integrate GLP-1 prescription data into market analysis and consider how pharmaceutical advances may reduce, postpone, or expand procedure demand. The pharmaceutical-sector trend is now a cross-industry trend that cannot be viewed in isolation.

Enabling Technologies Lead to Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are becoming essential components of modern clinical practice. Device manufacturers are investing in integrated technology platforms that support a procedure from planning through execution and follow-up. These systems create deeper and more durable customer relationships than standalone products.

Open-platform approaches are also increasing in availability, expanding flexibility while intensifying competition. As data become more critical, the companies that combine hardware, software, and clinical analytics will likely capture higher value. For medical device leaders, this means building competencies beyond reusable instruments and implants, including data engineering, user interface design, and systems integration.

Global Impact

Together these trends show that medtech is at the intersection of global health and economic transformation. China's procurement policies exert influence across supply chains and pricing in dozens of countries. Reimbursement decisions in the U.S. are shaping care models that other governments are adopting. Trade friction is forcing leaders to re-evaluate where to manufacture, where to invest, and which alliances matter. GLP-1 therapies are impacting not just patients but the financial viability of procedural medicine. Finally, digital platforms are becoming new strategic growth areas for economies that can support their development.

Strategic Insights

For executives, the essential priority is to create a more geographically integrated and policy-aware business strategy. Product portfolios must be aligned with regional pricing realities. Supply chains should be diversified before disruption occurs. R&D should account for sites of care, payment reform, and the growth of outpatient surgery. Companies also should assess the effect of metabolic therapies on multiple therapy areas and find investment opportunities in data-driven care. Multinational collaborations and public-private partnerships will have a growing role in medtech governance.

Future Outlook

The period from 2026 to 2031 will likely see medical devices evolve from discrete products to parts of interconnected health systems. Data generated by surgical robots and diagnostic platforms will become a measure of value. International procurement will drive lower price expectations in every region, forcing innovation to focus more on value and operational efficiency. Supply chain resilience will be a permanent investment priority. In emerging economies, local manufacturing capacity is expected to expand, while high-income countries may seek new subsidies and incentives to retain production. The medtech industry will become deeply embedded in global digital infrastructure, climate policy, and public health strategy.

Conclusion

Medical technology is a global strategic sector, intertwined with economic growth and geopolitical shifts. The structural changes emerging in 2026 are not isolated market developments. They are signals from a more fractious yet more connected world. Organizations that can anticipate these forces and adapt business models will create durable advantage.

Source

This article is based on Clarivate's blog, Medtech Trends to Watch in 2026, available at https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026